{
  "docId": "019dd923-622c-750b-8b98-916758668d1f",
  "docSlug": "34401c2968d1",
  "documentTitle": "Dexcom, Inc. (DXCM)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Ben Axler",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-03-21 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 55,
  "pageCount": 83,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a quote from Abbott's 4Q FY18 earnings call to support the thesis.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bar_chart_stacked",
    "line_chart",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-916758668d1f/55",
  "deckHref": "/decks/019dd923-622c-750b-8b98-916758668d1f",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-916758668d1f.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-916758668d1f#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "callout",
      "text": "We believe that Abbott’s demonstrated share dominance (92%) should grow even more pronounced in the near future with the release of the Libre 2",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35d886fa-63f5-4f7a-aeca-f8d673ef62b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Bloomberg Weekly New Prescriptions Written Relative Pharmacy Market Share, Dexcom vs. Abbott",
      "attrs": null,
      "subkind": "bar-stacked-100pct",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3a3be07-ecd6-49c0-8fa7-18aae8fe5e31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.51,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Bloomberg Weekly New Prescriptions Written Total New Prescriptions Written, Dexcom vs. Abbott",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c419efe5-a876-48bd-b20c-d677e29f8055",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Pharmacy Market Share: 92%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-f5d2-7501-bd8c-a14e3e972335",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Patient adoption trends through the pharmacy channel demonstrate that the Abbott has dominated Dexcom in recent share gains. Data provided by Symphony Health Solutions dating back to the first week of 2018 show that Abbott is currently capturing over 90% of the pharmacy channel when compared directly to Dexcom. We believe that this demonstrates that, after 4-5 years of CGM adoption among T1 diabetics, the strongest opportunity for future adoption lies among insulin-dependent T2 diabetics – and that the Libre is by far the best solution for these patients at current prices, and given Dexcom’s current lineup of CGMs.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "759b026a-a313-4816-acd1-935321c41bfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.51,
        "y": 0.76
      },
      "kind": "quote",
      "text": "We saw an accelerating trend of new users as we ramped up our awareness efforts during the second half of the year and pharmacy insurance coverage continued to increase including an emerging trend of seeing Libre granted preferred co-pay status versus competitive systems due to its compelling overall value proposition. - Abbott 4Q FY18 Conference Call (Jan 23, 2019)",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d09e67b1-f8f5-48e3-8a13-5bcbf5d28ea3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "We saw an accelerating trend of new users as we ramped up our awareness efforts during the second half of the year and pharmacy insurance coverage continued to increase including an emerging trend of seeing Libre granted preferred co-pay status versus competitive systems due to its compelling overall value proposition. — Abbott 4Q FY18 Conference Call (Jan 23, 2019)",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-f5d2-7501-bd8c-9d49b55ffd56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: Bloomberg Symphony Health Solutions. 1. Abbott new prescription data includes both Libre 10-Day and Libre 14-Day sensors. Dexcom new prescription data includes G4, G5, and G6 sensors.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49090da8-c74a-40ed-a55f-1f3a4986aa4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.31,
        "y": 0.03
      },
      "kind": "title",
      "text": "Recent Pharmacy Trends Confirm: Abbott Dominates Dexcom In New Patient Adds",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36815893-789b-4d81-a5d3-d5bc4c1e7077",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}